A description of the invention will be available after the patent application is published. Nencki Institute is the sole applicant. For more information contact Technology Transfer Office.
A description of the invention will be available after the patent application is published. Nencki Institute is the co-applicant with University of Warsaw and National Medicines Institutes. University of Warsaw is the leader in patent protection and commercialization-related activities. For more information contact Technology Transfer Office.
A description of the invention will be available after the patent application is published. Nencki Institute is the co-applicant with University of Warsaw. University of Warsaw is the leader in patent protection and commercialization-related activities. For more information contact Technology Transfer Office.
A description of the invention will be available after the patent application is published. Nencki Institute is the sole applicant. For more information contact Technology Transfer Office.
Isolated peptides, compositions and methods of use for treating tumors infiltrated with macrophages, such as glioblastoma. For more information contact Technology Transfer Office.
A panel of blood RNA markers for the prediction of epilepsy, in particular drug resistant epilepsy, in girls aged up to 24 months with tuberous sclerosis. Nencki Institute is the co-applicant with Medical University of Warsaw, International Institute of Molecular and Cell Biology in Warsaw, and Children’s Memorial Health Institute in Warsaw. Medical University of Warsaw is the leader in patent protection and commercialization-related activities. For more…
A panel of blood RNA markers for the prediction of the occurrence of epilepsy recurrence following drug withdrawal in patients with tuberous sclerosis. Nencki Institute is the co-applicant with Medical University of Warsaw, International Institute of Molecular and Cell Biology in Warsaw, and Children’s Memorial Health Institute in Warsaw. Medical University of Warsaw is the leader in patent protection and commercialization-related activities. For more…
Description of the invention will be available after the patent application is published.
Description of the invention will be available after the patent application is published.
Description of the invention will be available after the patent application is published.
Patent was granted in Poland and Nencki Institute is the sole applicant.
The subject of the present invention is a method for detecting active, remyelinating lesions in patients diagnosed with multiple sclerosis through the determination of changes in the levels of interleukin-33 in peripheral blood and cerebrospinal fluid, which constitutes a novel marker of endogenous repair processes facilitating the monitoring of the differentiation of oligodendrocyte precursor differentiation…
The present invention relates to methods for the identification of single nucleotide polymorphisms (SNP) in the GRHL1, GRHL2 and GRHL3 genes and the use of these polymorphisms as markers to identify patients at increased susceptibility to cancer of the kidneys.
The invention relates to the diagnosis of the pre-diabetoc state and processes underlying development of diabetic state way before blood glucose levels are abnormaln and diabetes clinical symptoms occur. This may be done using the relative proportion of the level of the Wnt4 and Wnt3a proteins in blood plasma. wew ew Briefly, in prediabetic state…
A device (1) for immobilizing an animal in order to examine a selected area of the animal’s body, the device (1) comprising two upright members (2a, 2b) secured by their lower ends to a base (3), the height of the upright members (2a, 2b) being adjustable independently of one another and being adapted to be…
This invention relates generally to the field of cancer diagnostics, and in particular to the detection of an increased risk of developing a skin cancer. Specifically, the present invention relates to a method of detecting and identifying an increased risk of developing a skin cancer in a human patient based on polymorphisms of the GRHL3…
The present invention relates to a genetically encoded FRET-based biosensor to monitor the activity of matrix metalloproteinase 9 (MMP-9). MMP-9 is an extracellular acting endopeptidase implicated in both physiological and pathological processes. A genetically encoded FRET biosensor anchored in the cellular membrane allows studying the proteolytic activity of MMP-9 with high spatiotemporal resolution at the…
The present invention is related to use of marimastat or a pharmaceutically acceptable salt, solvate or polymorph thereof in preventing or treating epileptogenesis in a subject that suffered a brain insult. Said brain insult is a stroke, traumatic brain injury, or a result of status epilepticus, evoked by structural or metabolic reasons. Marimastat or a…